NYSE:MRK News 30 November 2025

Merck (MRK) Stock After Hours on Dec. 12, 2025: Winrevair EU Tailwind, Analyst Targets, and What to Watch Before the Next Open

Merck & Company, Inc. (NYSE: MRK) ended Friday, December 12, 2025, as a relative bright spot in a broadly weak session for U.S. equities. The stock closed at $100.30 (+1.30%), extending its winning streak to three straight days even as

13 December 2025

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in

12 December 2025

Financial Forecasts · Investment Analysis · NYSE:MRK · Patent News · Pharmaceuticals · Stock Market

Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck & Co., Inc. (NYSE: MRK) heads into mid‑December with its stock back near the psychologically important $100 level—and with the kind of headline mix that makes long-term pharma investing feel like chess played on a trampoline: upbeat analyst upgrades

12 December 2025

Analyst Forecasts · Financial Updates · Investment Tips · Merck News · NYSE:MRK · Stock Market

Merck (MRK) Stock After Hours on December 10, 2025: What to Watch Before the December 11 Open

Merck & Co., Inc. (NYSE: MRK) heads into the December 11, 2025 U.S. trading session with its share price stabilizing after a volatile stretch driven by earnings, pipeline news, and a major flu-drug acquisition. Here’s a structured look at what

11 December 2025

After Hours Trading · Financial News · Investment Tips · Merck · NYSE:MRK · Stock Market

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. (NYSE: MRK) stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow

10 December 2025

Analyst Insights · Dividend Investing · Market Trends · NYSE:MRK · Pharmaceuticals · Stock Analysis

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda

10 December 2025

Financial Forecasts · Healthcare Industry · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the

10 December 2025

After-Hours Trading · Keytruda · Merck · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a

8 December 2025

Company News · Financial Analysis · Investing · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt

7 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life

2 December 2025

Dividends · FDA Approvals · NYSE:MRK · Pharmaceuticals · Stock Market · Wall Street Analysis

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck & Co. (NYSE: MRK) is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid‑stage data for heart drug Winrevair, and fresh deal‑making have pushed the share price close to its

30 November 2025

Analyst Forecasts · Financial News · Investment · Merck · NYSE:MRK · Stock Market

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck & Co., Inc. (NYSE: MRK) heads into the Monday, December 1, 2025 market open riding one of the strongest monthly rallies in the S&P 500, powered by upbeat earnings, dividend growth and a string of bullish analyst calls focused

30 November 2025

Earnings Preview · Investment Strategies · Market Outlook · NYSE:MRK · Pharma Industry · Stock Analysis

NYSE:MRK News 30 November 2025 - 13 December 2025